NEUTROGUARD study: Phase III clinical study of DEFENCATH for prevention of CLABSI in adults on TPN via central venous catheter.

Good morning, and welcome to the CorMedix Fourth Quarter and Full Year 2025 Earnings and Corporate Update Conference Call. Leading the call tod ...